Epidermal growth factor receptor directed therapy in head and neck cancer

Critical Reviews in Oncology/Hematology

Volumn 57, Issue 1, 2006, Pages 25-43

  Choong, Nicholas W ^a   Cohen, Ezra E W ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

Anti sense oligonucleotide; Epidermal growth factor receptor; Head and neck neoplasm; Immunotoxin conjugate; Monoclonal antibody; Quinazoline; Squamous cell carcinoma

Indexed keywords

6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; 6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLUOROURACIL; GEFITINIB; HYDROXYUREA; IMMUNOTOXIN; LAPATINIB; MATUZUMAB; MDX 447; METHOTREXATE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY H R3; PACLITAXEL; PANITUMUMAB; PELITINIB; PLATINUM; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; VANDETANIB;

ACNE; ANOREXIA; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CARDIOMYOPATHY; CAUSE OF DEATH; CHEMOTHERAPY; CLINICAL TRIAL; CYTOTOXICITY; DERMATITIS; DEVELOPING COUNTRY; DIARRHEA; DOSE RESPONSE; DRY SKIN; FATIGUE; FEVER; HEAD AND NECK CANCER; HEADACHE; HUMAN; INCIDENCE; METASTASIS; MUCOSA INFLAMMATION; NEUROPATHY; NEUTROPENIA; PATHOGENESIS; PREDICTION; PROGNOSIS; PROTEIN FUNCTION; QT PROLONGATION; RASH; REVIEW; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; STOMATITIS; THROMBOCYTOPENIA;

ANTIBODIES, MONOCLONAL; CARCINOMA, SQUAMOUS CELL; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOTOXINS; OLIGONUCLEOTIDES, ANTISENSE; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 29144446003     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2005.06.002     Document Type: Review

References (201)

1. K. Shibuya, C.D. Mathers, C. Boschi-Pinto, A.D. Lopez, and C.J. Murray Global and regional estimates of cancer mortality and incidence by site: II. Results for the global burden of disease 2000 BMC Cancer 2 2002 37
2. A. Jemal, R.C. Tiwari, and T. Murray Cancer statistics CA Cancer J Clin 54 2004 8 29
3. M.R. Spitz, J.J. Fueger, H. Goepfert, W.K. Hong, and G.R. Newell Squamous cell carcinoma of the upper aerodigestive tract. A case comparison analysis Cancer 61 1988 203 208
4. E.L. Wynder, and S.D. Stellman Impact of long-term filter cigarette usage on lung and larynx cancer risk: a case-control study J Natl Cancer Inst 62 1979 471 477
5. J.A. Brennan, J.O. Boyle, and W.M. Koch Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck N Engl J Med 332 1995 712 717
6. L. Gissmann, L. Wolnik, H. Ikenberg, U. Koldovsky, H.G. Schnurch, and H. zur Hausen Human papillomavirus types 6 and 11 DNA sequences in genital and laryngeal papillomas and in some cervical cancers Proc Natl Acad Sci USA 80 1983 560 563
7. H. Mineta, T. Ogino, and H.M. Amano Human papilloma virus (HPV) type 16 and 18 detected in head and neck squamous cell carcinoma Anticancer Res 18 1998 4765 4768
8. J. Mork, A.K. Lie, and E. Glattre Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck N Engl J Med 344 2001 1125 1131
9. R. Fahraeus, H.L. Fu, and I. Ernberg Expression of Epstein-Barr virus-encoded proteins in nasopharyngeal carcinoma Int J Cancer 42 1988 329 338
10. J.S. Cooper, T.F. Pajak, and A.A. Forastiere Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck N Engl J Med 350 2004 1937 1944
11. J. Bernier, C. Domenge, and M. Ozsahin Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer N Engl J Med 350 2004 1945 1952
12. J.P. Pignon, J. Bourhis, C. Domenge, and L. Designe Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer Lancet 355 2000 949 955
13. Bourhis J, Amand C, Pignon J-P. Update of MACH-NC (Meta-Analysis of Chemotherapy in Head & Neck Cancer) database focused on concomitant chemoradiotherapy. J Clin Oncol 2004; 22 [Abstract 5505].
14. A.A. Forastiere, B. Metch, and D.E. Schuller Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study J Clin Oncol 10 1992 1245 1251
15. M. Clavel, J.B. Vermorken, and F. Cognetti Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase III study of the EORTC Head and Neck Cancer Cooperative Group Ann Oncol 5 1994 521 526
16. L. De Andres, J. Brunet, and A. Lopez-Pousa Randomized trial of neoadjuvant cisplatin and fluorouracil versus carboplatin and fluorouracil in patients with stage IV-M0 head and neck cancer J Clin Oncol 13 1995 1493 1500
17. C. Jacobs, G. Lyman, and E. Velez-Garcia A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck J Clin Oncol 10 1992 257 263
18. V. Adamo, G. Ferraro, and S. Pergolizzi Paclitaxel and cisplatin in patients with recurrent and metastatic head and neck squamous cell carcinoma Oral Oncol 40 2004 525 531
19. L. Specht, S.K. Larsen, and H.S. Hansen Phase II study of docetaxel and cisplatin in patients with recurrent or disseminated squamous-cell carcinoma of the head and neck Ann Oncol 11 2000 845 849
20. J. Califano, P. van der Riet, and W. Westra Genetic progression model for head and neck cancer: implications for field cancerization Cancer Res 56 1996 2488 2492
21. Q. Huang, G.P. Yu, and S.A. McCormick Genetic differences detected by comparative genomic hybridization in head and neck squamous cell carcinomas from different tumor sites: construction of oncogenetic trees for tumor progression Genes Chromosomes Cancer 34 2002 224 233
22. G.A. Jeon, J.S. Lee, and V. Patel Global gene expression profiles of human head and neck squamous carcinoma cell lines Int J Cancer 112 2004 249 258
23. Y.J. Chen, S.C. Lin, and T. Kao Genome-wide profiling of oral squamous cell carcinoma J Pathol 204 2004 326 332
24. P. Blume-Jensen, and T. Hunter Oncogenic kinase signalling Nature 411 2001 355 365
25. R. Levi-Montalcini Effects of mouse tumor transplantation on the nervous system Ann NY Acad Sci 55 1952 330 344
26. S. Cohen The stimulation of epidermal proliferation by a specific protein (EGF) Dev Biol 12 1965 394 407
27. G. Carpenter, K.J. Lembach, M.M. Morrison, and S. Cohen Characterization of the binding of 125-I-labeled epidermal growth factor to human fibroblasts J Biol Chem 250 1975 4297 4304
28. A. Ullrich, L. Coussens, and J.S. Hayflick Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells Nature 309 1984 418 425
29. Y. Yarden, and M.X. Sliwkowski Untangling the ErbB signalling network Nat Rev Mol Cell Biol 2 2001 127 137
30. T.S. Lewis, P.S. Shapiro, and N.G. Ahn Signal transduction through MAP kinase cascades Adv Cancer Res 74 1998 49 139
31. J. Blenis Signal transduction via the MAP kinases: proceed at your own RSK Proc Natl Acad Sci USA 90 1993 5889 5892
32. T.O. Chan, S.E. Rittenhouse, and P.N. Tsichlis AKT/PKB and other D3 phosphoinositide-regulated kinases: kinase activation by phosphoinositide- dependent phosphorylation Annu Rev Biochem 68 1999 965 1014
33. B.M. Burgering, and P.J. Coffer Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction Nature 376 1995 599 602
34. K. Matuoka, F. Shibasaki, M. Shibata, and T. Takenawa Ash/Grb-2, a SH2/SH3-containing protein, couples to signaling for mitogenesis and cytoskeletal reorganization by EGF and PDGF Embo J 12 1993 3467 3473
35. M.L. Kuo, S.E. Chuang, M.T. Lin, and S.Y. Yang The involvement of PI 3-K/Akt-dependent up-regulation of Mcl-1 in the prevention of apoptosis of Hep3B cells by interleukin-6 Oncogene 20 2001 677 685
36. T. Suhara, T. Mano, B.E. Oliveira, and K. Walsh Phosphatidylinositol 3-kinase/Akt signaling controls endothelial cell sensitivity to Fas-mediated apoptosis via regulation of FLICE-inhibitory protein (FLIP) Circ Res 89 2001 13 19
37. S.R. Datta, H. Dudek, and X. Tao Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery Cell 91 1997 231 241
38. A.C. Newton, and J.E. Johnson Protein kinase C: a paradigm for regulation of protein function by two membrane-targeting modules Biochim Biophys Acta 1376 1998 155 172
39. J.I. Song, and J.R. Grandis STAT signaling in head and neck cancer Oncogene 19 2000 2489 2495
40. J. Bromberg, and J.E. Darnell Jr. The role of STATs in transcriptional control and their impact on cellular function Oncogene 19 2000 2468 2473
41. D.W. Threadgill, A.A. Dlugosz, and L.A. Hansen Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype Science 269 1995 230 234
42. P.J. Miettinen, J.E. Berger, and J. Meneses Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor Nature 376 1995 337 341
43. M. Sibilia, and E.F. Wagner Strain-dependent epithelial defects in mice lacking the EGF receptor Science 269 1995 234 238
44. N.C. Luetteke, T.H. Qiu, and S.E. Fenton Targeted inactivation of the EGF and amphiregulin genes reveals distinct roles for EGF receptor ligands in mouse mammary gland development Development 126 1999 2739 2750
45. T.J. Velu, L. Beguinot, and W.C. Vass Epidermal-growth-factor-dependent transformation by a human EGF receptor proto-oncogene Science 238 1987 1408 1410
46. J.R. Grandis, M.F. Melhem, E.L. Barnes, and D.J. Tweardy Quantitative immunohistochemical analysis of transforming growth factor-alpha and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck Cancer 78 1996 1284 1292
47. J. Santini, J.L. Formento, and M. Francoual Characterization, quantification, and potential clinical value of the epidermal growth factor receptor in head and neck squamous cell carcinomas Head Neck 13 1991 132 139
48. O. Dassonville, J.L. Formento, and M. Francoual Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer J Clin Oncol 11 1993 1873 1878
49. J.R. Grandis, and D.J. Tweardy Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer Cancer Res 53 1993 3579 3584
50. J.R. Grandis, D.J. Tweardy, and M.F. Melhem Asynchronous modulation of transforming growth factor alpha and epidermal growth factor receptor protein expression in progression of premalignant lesions to head and neck squamous cell carcinoma Clin Cancer Res 4 1998 13 20
51. D.M. Shin, J.Y. Ro, W.K. Hong, and W.N. Hittelman Dysregulation of epidermal growth factor receptor expression in premalignant lesions during head and neck tumorigenesis Cancer Res 54 1994 3153 3159
52. D.P. Slaughter, H.W. Southwick, and W. Smejkal Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin Cancer 6 1953 963 968
53. J.H. Kearsley, J.H. Leonard, M.D. Walsh, and G.R. Wright A comparison of epidermal growth factor receptor (EGFR) and c-erbB-2 oncogene expression in head and neck squamous cell carcinomas Pathology 23 1991 189 194
54. J.P. Rodrigo, S. Ramos, P.S. Lazo, I. Alvarez, and C. Suarez Amplification of ERBB oncogenes in squamous cell carcinomas of the head and neck Eur J Cancer 32A 1996 2004 2010
55. R. Werkmeister, B. Brandt, and U. Joos The erbB oncogenes as prognostic markers in oral squamous cell carcinomas Am J Surg 172 1996 681 683
56. R. Werkmeister, B. Brandt, and U. Joos Clinical relevance of erbB-1 and -2 oncogenes in oral carcinomas Oral Oncol 36 2000 100 105
57. P. O-charoenrat, P. Rhys-Evans, and S. Eccles Characterization of ten newly-derived human head and neck squamous carcinoma cell lines with special reference to c-erbB proto-oncogene expression Anticancer Res 21 2001 1953 1963
58. R. Todd, B.R. Donoff, and R. Gertz TGF-alpha and EGF-receptor mRNAs in human oral cancers Carcinogenesis 10 1989 1553 1556
59. H. Buerger, F. Gebhardt, and H. Schmidt Length and loss of heterozygosity of an intron 1 polymorphic sequence of egfr is related to cytogenetic alterations and epithelial growth factor receptor expression Cancer Res 60 2000 854 857
60. F. Gebhardt, K.S. Zanker, and B. Brandt Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1 J Biol Chem 274 1999 13176 13180
61. W. Liu, F. Innocenti, P. Chen, S. Das, E.H. Cook Jr., and M.J. Ratain Interethnic difference in the allelic distribution of human epidermal growth factor receptor intron 1 polymorphism Clin Cancer Res 9 2003 1009 1012
62. W. Liu, F. Innocenti, and M.H. Wu A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter Cancer Res 65 2005 46 53
63. W. Xia, Y.K. Lau, and H.Z. Zhang Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members Clin Cancer Res 5 1999 4164 4174
64. P. O-charoenrat, P.H. Rhys-Evans, D.J. Archer, and S.A. Eccles C-erbB receptors in squamous cell carcinomas of the head and neck: clinical significance and correlation with matrix metalloproteinases and vascular endothelial growth factors Oral Oncol 38 2002 73 80
65. S. Storkel, T. Reichert, K.A. Reiffen, and W. Wagner EGFR and PCNA expression in oral squamous cell carcinomas - a valuable tool in estimating the patient's prognosis Eur J Cancer B Oral Oncol 29B 1993 273 277
66. J.H. Leonard, J.H. Kearsley, G. Chenevix-Trench, and N.K. Hayward Analysis of gene amplification in head-and-neck squamous-cell carcinoma Int J Cancer 48 1991 511 515
67. M.E. Christensen, F. Engbaek, M.H. Therkildsen, P. Bretlau, and E. Nexo A sensitive enzyme-linked immunosorbent assay used for quantitation of epidermal growth factor receptor protein in head and neck carcinomas: evaluation, interpretations and limitations Br J Cancer 72 1995 1487 1493
68. Q.H. Wen, T. Miwa, T. Yoshizaki, I. Nagayama, M. Furukawa, and H. Nishijima Prognostic value of EGFR and TGF-alpha in early laryngeal cancer treated with radiotherapy Laryngoscope 106 1996 884 888
69. J. Rubin Grandis, M.F. Melhem, and W.E. Gooding Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival J Natl Cancer Inst 90 1998 824 832
70. A.J. Barker, K.H. Gibson, and W. Grundy Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer Bioorg Med Chem Lett 11 2001 1911 1914
71. A.E. Wakeling, S.P. Guy, and J.R. Woodburn ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy Cancer Res 62 2002 5749 5754
72. N. Magne, J.L. Fischel, and A. Dubreuil Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 ("Iressa") Br J Cancer 86 2002 1518 1523
73. S.M. Huang, J. Li, E.A. Armstrong, and P.M. Harari Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa) Cancer Res 62 2002 4300 4306
74. J. Baselga, D. Rischin, and M. Ranson Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types J Clin Oncol 20 2002 4292 4302
75. R.S. Herbst, A.M. Maddox, and M.L. Rothenberg Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial J Clin Oncol 20 2002 3815 3825
76. M. Ranson, L.A. Hammond, and D. Ferry ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial J Clin Oncol 20 2002 2240 2250
77. P.M. LoRusso, R.S. Herbst, and D. Rischin Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors Clin Cancer Res 9 2003 2040 2048
78. K. Nakagawa, T. Tamura, and S. Negoro Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors Ann Oncol 14 2003 922 930
79. E.E. Cohen, F. Rosen, and W.M. Stadler Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck J Clin Oncol 21 2003 1980 1987
80. Wheeler RH, Jones D, Sharma P, et al. Clinical and molecular phase II study of gefitinib in patients (pts) with recurrent squamous cell cancer of the head and neck (H&N Ca). Proc Am Soc Clin Oncol 2005 [Abstract 5531].
81. Kane MA, Cohen E, List M, et al. Phase II study of 250 mg gefitinib in advanced squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol 2004;22 [Abstract 5586].
82. M.G. Kris, R.B. Natale, and R.S. Herbst Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial JAMA 290 2003 2149 2158
83. M. Fukuoka, S. Yano, and G. Giaccone Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer J Clin Oncol 21 2003 2237 2246
84. Belón J, Irigoyen A, Rodríguez I, et al. Preliminary results of a Phase II study to evaluate gefitinib combined with docetaxel and cisplatin in patients with recurrent and/or metastatic squamous-cell carcinoma of the head and neck. Proc Am Soc Clin Oncol 2005 [Abstract 5563].
85. Cohen EE, Haraf DJ, Stenson KM, et al. Integration of Gefitinib (G), into a Concurrent Chemoradiation (CRT) Regimen Followed by G Adjuvant Therapy in Patients with Locally Advanced Head and Neck Cancer (HNC) - a Phase II Trial. Proc Am Soc Clin Oncol 2005 [Abstract 5506].
86. K.C. Chan, W.F. Knox, and J.M. Gee Effect of epidermal growth factor receptor tyrosine kinase inhibition on epithelial proliferation in normal and premalignant breast Cancer Res 62 2002 122 128
87. Gustin D, Haraf DJ, Stenson K, et al. Treatment of advanced head and neck cancer with induction chemotherapy followed by chemoradiotherapy with reduced radiation dose. J Clin Oncol 2004;22 [Abstract 5546].
88. E.E. Vokes, K. Stenson, and F.R. Rosen Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer J Clin Oncol 21 2003 320 326
89. Raben D, Kane M, Chen C, et al. Update on the toxicity and response of a phase I trial of concurrent, daily gefitinib and radiation or chemo-radiation for patients with locally advanced squamous cell cancer of the head and neck (LASCCHN). Eur J Cancer 2004;2(Suppl.) [Abstract 649].
90. V.A. Pollack, D.M. Savage, and D.A. Baker Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice J Pharmacol Exp Ther 291 1999 739 748
91. M. Hidalgo, L.L. Siu, and J. Nemunaitis Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies J Clin Oncol 19 2001 3267 3279
92. N. Yamamoto, Y. Yamada, and T. Shimoyama A phase I study of erlotinib HCl in Japanese patients with various types of solid tumors Proc Am Soc Clin Oncol 22 2003 225
93. D. Soulieres, N.N. Senzer, E.E. Vokes, M. Hidalgo, S.S. Agarwala, and L.L. Siu Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck J Clin Oncol 22 2004 77 85
94. Forero L, Patnaik A, Hammond LA, et al. Phase I, pharmacokinetic (PK) and biologic study of OSI-774, a selective epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitor in combination with paclitaxel and carboplatin. Proc Am Soc Clin Oncol 2002;19 [Abstract 1908].
95. Forouzesh B, Hidalgo M, Takimoto C, et al. Phase I, pharmacokinetic (PK), and biological studies of the epidermal growth factor-tyrosine kinase (EGFR-TK) inhibitor OSI-774 in combination with docetaxel. Proc Am Soc Clin Oncol 2002;19 [Abstract 81].
96. Desai AA, Janisch L, George CM, et al. Phase I and pharmacokinetic study of erlotonib HCL (E; OSI-774) in combination with capecitabine (C) in patients with advanced solid tumors. Proc Am Soc Clin Oncol 2003;22 [Abstract 900].
97. Kim ES, Kies M, Sabichi A, et al. Phase II study of combination cisplatin, docetaxel and erlotinib in patients with metastatic/recurrent head and neck squamous cell carcinoma (HNSCC). Proc Am Soc Clin Oncol 2005 [Abstract 5546].
98. A. Viloria-Petit, T. Crombet, and S. Jothy Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis Cancer Res 61 2001 5090 5101
99. F. Ciardiello, R. Caputo, and R. Bianco Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor Clin Cancer Res 6 2000 2053 2063
100. Vokes EE, Cohen EE, Mauer AM, et al. A phase I study of erlotinib and bevacizumab for recurrent or metastatic squamous cell carcinoma of the head and neck (HNC). Proc Am Soc Clin Oncol 2005 [Abstract 5504].
101. Mauer AM, Cohen EEW, Wong SJ, et al. Phase I study of epidermal growth factor receptor (EGFR) inhibitor, erlotinib, and vascular endothelial growth factor monoclonal antibody, bevacizumab, in recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol 2004;22 [Abstract 5539].
102. L.N. Klapper, S. Glathe, and N. Vaisman The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors Proc Natl Acad Sci USA 96 1999 4995 5000
103. R. Pinkas-Kramarski, L. Soussan, and H. Waterman Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions Embo J 15 1996 2452 2467
104. D. Karunagaran, E. Tzahar, and R.R. Beerli ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer Embo J 15 1996 254 264
105. M. Alimandi, A. Romano, and M.C. Curia Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas Oncogene 10 1995 1813 1821
106. D.W. Rusnak, K. Lackey, and K. Affleck The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo Mol Cancer Ther 1 2001 85 94
107. E.R. Wood, A.T. Truesdale, and O.B. McDonald A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells Cancer Res 64 2004 6652 6659
108. H.A. Burris, C. Taylor, and S. Jones A phase I study of GW572016 in patients with solid tumors Proc Am Soc Clin Oncol 22 2003 248
109. Versola M, Burris HA, Jones S, et al. Clinical activity of GW572016 in EGF10003 in patients with solid tumors. J Clin Oncol 2004 [Abstract 22].
110. N. Spector, E. Raefsky, and H. Hurwitz Safety, clinical efficacy, and biologic assessments from EGF10004: A randomized phase IB study of GW572016 for patients with metastatic carcinomas overexpressing EGFR or erbB2 Proc Am Soc Clin Oncol 22 2003 193
111. Minami H, Nakagawa K, Kawada K, et al. A phase I study of GW572016 in patients with solid tumors. J Clin Oncol 2004;22 [Abstract 3048].
112. D.L. Keefe Trastuzumab-associated cardiotoxicity Cancer 95 2002 1592 1600
113. Pandite L, Burris HA, Jones S, et al. A safety, tolerability, and pharmacokinetic (PK) study of GW572016 in patients with solid tumors. J Clin Oncol 2004;22 [Abstract 3179].
114. C.J. Torrance, P.E. Jackson, and E. Montgomery Combinatorial chemoprevention of intestinal neoplasia Nat Med 6 2000 1024 1028
115. A. Wissner, M.B. Brawner Floyd, and S.K. Rabindran Syntheses and EGFR and HER-2 kinase inhibitory activities of 4-anilinoquinoline-3-carbonitriles: analogues of three important 4-anilinoquinazolines currently undergoing clinical evaluation as therapeutic antitumor agents Bioorg Med Chem Lett 12 2002 2893 2897
116. Hidalgo M, Erlichman C, Rowinsky EK, et al. Phase 1 trial of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor (EGFR), in patients with advanced solid tumors. Proc Am Soc Clin Oncol 2002;21 [Abstract 65].
117. Traxler P, Buchdunger E, Furet P, et al. Preclinical profile of PKI166 - a novel and potent EGFR tyrosine kinase inhibitor for clinical development. Proc Am Assoc Cancer Res 1999 [Abstract 100].
118. I.K. Mellinghoff, C. Tran, and C.L. Sawyers Growth inhibitory effects of the dual ErbB1/ErbB2 tyrosine kinase inhibitor PKI-166 on human prostate cancer xenografts Cancer Res 62 2002 5254 5259
119. K.L. Weber, M. Doucet, J.E. Price, C. Baker, S.J. Kim, and I.J. Fidler Blockade of epidermal growth factor receptor signaling leads to inhibition of renal cell carcinoma growth in the bone of nude mice Cancer Res 63 2003 2940 2947
120. S.J. Kim, H. Uehara, and S. Yazici Simultaneous blockade of platelet-derived growth factor-receptor and epidermal growth factor-receptor signaling and systemic administration of paclitaxel as therapy for human prostate cancer metastasis in bone of nude mice Cancer Res 64 2004 4201 4208
121. J.N. Myers, F.C. Holsinger, and B.N. Bekele Targeted molecular therapy for oral cancer with epidermal growth factor receptor blockade: a preliminary report Arch Otolaryngol Head Neck Surg 128 2002 875 879
122. F.C. Holsinger, D.D. Doan, and S.A. Jasser Epidermal growth factor receptor blockade potentiates apoptosis mediated by Paclitaxel and leads to prolonged survival in a murine model of oral cancer Clin Cancer Res 9 2003 3183 3189
123. R. Hoekstra, H. Dumez, and A.T. van Oosterom A phase I and pharmacological study of PKI166, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, administered orally in a two weeks on, two weeks off scheme to patients with advanced cancer Proc Am Soc Clin Oncol 21 2002 86a
124. H. Dumez, R. Hoekstra, and F. Eskens A phase I and pharmacological study of PKI166, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, administered orally 3 times a week to patients with advanced cancer Proc Am Soc Clin Oncol 21 2002 86a
125. S.M. Huang, J.M. Bock, and P.M. Harari Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck Cancer Res 59 1999 1935 1940
126. S.M. Huang, J. Li, and P.M. Harari Molecular inhibition of angiogenesis and metastatic potential in human squamous cell carcinomas after epidermal growth factor receptor blockade Mol Cancer Ther 1 2002 507 514
127. F. Ciardiello, R. Bianco, and V. Damiano Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225 Clin Cancer Res 5 1999 909 916
128. P.M. Harari, and S.M. Huang Head and neck cancer as a clinical model for molecular targeting of therapy: combining EGFR blockade with radiation Int J Radiat Oncol Biol Phys 49 2001 427 433
129. L. Milas, K. Mason, and N. Hunter In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody Clin Cancer Res 6 2000 701 708
130. F. Robert, M.P. Ezekiel, and S.A. Spencer Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer J Clin Oncol 19 2001 3234 3243
131. Pfister DG, Aliff TB, Kraus DH, et al. Concurrent cetuximab, cisplatin, and concomitant boost radiation therapy (RT) for locoregionally advanced, squamous cell head and neck cancer (SCCHN): Preliminary evaluation of a new combined-modality paradigm. Proc Am Soc Clin Oncol 2003;22 [Abstract 1993].
132. Su YB, Kraus DH, Zelefsky MJ, et al. Concurrent cetuximab, cisplatin, and radiotherapy (RT) for loco-regionally advanced squamous cell carcinoma of the head and neck (SCCHN): updated results of a novel combined modality paradigm. Proc Am Soc Clin Oncol 2005 [Abstract 5529].
133. Bonner JA, Giralt J, Harari PM, et al. Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: a phase III study of high dose radiation therapy with or without cetuximab. J Clin Oncol 2004;22 [Abstract 5507].
134. P.M. Harari, W.F. Durland, P. Chinnaiyan, and G.K. Hartig Impact of the EGFR inhibitor C225 on wound healing in advanced head & neck cancer patients undergoing neck dissection Proc Am Soc Clin Oncol 22 2003 220
135. Bonner JA, Harari PM, Giralt J, et al. Improved preservation of larynx with the addition of cetuximab to radiation for cancers of the larynx and hypopharynx. Proc Am Soc Clin Oncol 2005 [Abstract 5533].
136. J. Baselga, D. Pfister, and M.R. Cooper Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin J Clin Oncol 18 2000 904 914
137. D.M. Shin, N.J. Donato, and R. Perez-Soler Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer Clin Cancer Res 7 2001 1204 1213
138. Humblet Y, Vega-Villegas E, Mesia R, et al. Phase I study of cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil (5-FU) in patients (pts) with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol 2004;22 [Abstract 5513].
139. Vega-Villegas E, Awada A, Mesia R, et al. A phase I study of cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil (5-FU) in patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R&M SCCHN). Proc Am Soc Clin Oncol 2003 [Abstract 2020].
140. Burtness BA, Li Y, Flood W, Mattar BI, Forastiere A. Phase III randomized trial of cisplatin + placebo versus cisplatin + C225, a monoclonal antibody directed to the epidermal growth factor-receptor: An Eastern Cooperative Oncology Group trial. Proc Am Assoc Cancer Res 2003 [Abstract 77].
141. Vermorken J, Bourhis J, Trigo J, et al. Cetuximab (Erbitux) in recurrent/metastatic (R&M) squamous cell carcinoma of the head and neck (SCCHN) refractory to first-line platinum-based therapies. Proc Am Soc Clin Oncol 2005 [Abstract 5505].
142. Trigo J, Hitt R, Koralewski P, et al. Cetuximab monotherapy is active in patients (pts) with platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN): results of a phase II study. J Clin Oncol 2004;22 [Abstract 5502].
143. Kies MS, Arquette MA, Nabell L, et al. Final report of the efficacy and safety of the anti-epidermal growth factor antibody Erbitux (IMC-C225), in combination with cisplatin in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN) refractory to cisplatin containing chemotherapy. Proc Am Soc Clin Oncol 2002 [Abstract 925].
144. Baselga J, Trigo JM, Bourhis J, et al. Cetuximab (C225) plus cisplatin/carboplatin is active in patients (pts) with recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) progressing on a same dose and schedule platinum-based regimen. Proc Am Soc Clin Oncol 2002; 21 [Abstract 900].
145. Chan ATC, Hsu MM, Goh BC, et al. A phase II study of cetuximab (C225) in combination with carboplatin in patients (pts) with recurrent or metastatic nasopharyngeal carcinoma (NPC) who failed to a platinum-based chemotherapy. Proc Am Soc Clin Oncol 2003; 22 [Abstract 2000].
146. C.A. Kettleborough, J. Saldanha, V.J. Heath, C.J. Morrison, and M.M. Bendig Humanization of a mouse monoclonal antibody by CDR-grafting: the importance of framework residues on loop conformation Protein Eng 4 1991 773 783
147. Burger AM, Heiss NS, Kreysch H. The humanized monoclonal anti-EGFR antibody EMD72000 potently inhibits the growth of EGFR-expressing human tumor xenografts insensitive to chemotherapeutic drugs. Proc Am Assoc Cancer Res 2003;44 [Abstract 5719].
148. J.R. Grandis, A. Chakraborty, M.F. Melhem, Q. Zeng, and D.J. Tweardy Inhibition of epidermal growth factor receptor gene expression and function decreases proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells Oncogene 15 1997 409 416
149. Amendt C, Mantell O, Peters M. In vivo activity of humanized monoclonal anti-EGFR antibody EMD72000 in combination with gemcitabine on growth of primary tumors and metastases in an orthotopic nude mouse model. Proc Am Assoc Cancer Res 2003;44 [Abstract 6180].
150. T. Hoffmann, D. Hafner, H. Ballo, I. Haas, and H. Bier Antitumor activity of anti-epidermal growth factor receptor monoclonal antibodies and cisplatin in ten human head and neck squamous cell carcinoma lines Anticancer Res 17 1997 4419 4425
151. H. Bier, T. Hoffmann, and U. Hauser Clinical trial with escalating doses of the antiepidermal growth factor receptor humanized monoclonal antibody EMD 72 000 in patients with advanced squamous cell carcinoma of the larynx and hypopharynx Cancer Chemother Pharmacol 47 2001 519 524
152. U. Vanhoefer, M. Tewes, and F. Rojo Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor J Clin Oncol 22 2004 175 184
153. Salazar R, Tabernero J, Rojo F, et al. Dose-dependent inhibition of the EGFR and signalling pathways with the anti-EGFR monoclonal antibody (MAb) EMD 72000 administered every three weeks (q3w). A phase I pharmacokinetic/ pharmacodynamic (PK/PD) study to define the optimal biological dose (OBD). J Clin Oncol 2004;22 [Abstract 2002].
154. C. Mateo, E. Moreno, K. Amour, J. Lombardero, W. Harris, and R. Perez Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: recovery of antagonistic activity Immunotechnology 3 1997 71 81
155. T. Crombet-Ramos, J. Rak, R. Perez, and A. Viloria-Petit Antiproliferative, antiangiogenic and proapoptotic activity of h-R3: a humanized anti-EGFR antibody Int J Cancer 101 2002 567 575
156. Winquist E, Nabid A, Sicheri D, et al. A phase I dose escalation study of a humanized monoclonal antibody to EGFR (hR3) in patients with locally advanced squamous cell cancer of the head and neck (SCCHN) treated with radiotherapy (RT). Proc Am Soc Clin Oncol 2003;22 [Abstract 926].
157. T. Crombet, M. Osorio, and T. Cruz Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients J Clin Oncol 22 2004 1646 1654
158. N. Iznaga-Escobar, I.L. Ramirez, J.C. Izquierdo, L. Suarez, D. Morales, and R. Perez-Rodriguez 188Re-labeled anti-epidermal growth factor receptor humanized monoclonal antibody h-R3: labeling conditions, in vitro and in vivo stability Methods Find Exp Clin Pharmacol 25 2003 703 711
159. P. Riva, M. Santimaria, M. Casi, M. Adamo, R. Nada, and N. Inzaga Loco-regional radioimmunotherapy of malignant glioma by means of a humanised antibody hR3 (raised against epidermal growth factor receptors) labelled with Y-90 Proc Am Soc Clin Oncol 22 2003 112
160. X.D. Yang, X.C. Jia, J.R. Corvalan, P. Wang, and C.G. Davis Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy Crit Rev Oncol Hematol 38 2001 17 23
161. X.D. Yang, X.C. Jia, J.R. Corvalan, P. Wang, C.G. Davis, and A. Jakobovits Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy Cancer Res 59 1999 1236 1243
162. Yang XD, Wang P, Fredlin P, Jia XC, Oppenheim JJ, Davis CG. Preclinical evaluation of ABX-EGF as a potent anti-tumor agent. Proc Am Assoc Cancer Res 2002;43 [Abstract 4977].
163. Figlin RA, Belldegrun AS, Crawford J, et al. ABX-EGF, a fully human anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) in patients with advanced cancer: phase 1 clinical results. Proc Am Soc Clin Oncol 2002;21 [Abstract 35].
164. P.M. Guyre, R.F. Graziano, B.A. Vance, P.M. Morganelli, and M.W. Fanger Monoclonal antibodies that bind to distinct epitopes on Fc gamma RI are able to trigger receptor function J Immunol 143 1989 1650 1655
165. Pfister D, Alla L, Rober B, et al. A phase I trial of the epidermal growth factor receptor (EGFR)-directed bispecific antibody (BsAB) MDX-447 in patients with solid tumors. Proc Am Soc Clin Oncol 1999;16 [Abstract 1667].
166. G. Giaccone, J.L. Gonzalez-Larriba, and A.T. van Oosterom Combination therapy with gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, gemcitabine and cisplatin in patients with advanced solid tumors Ann Oncol 15 2004 831 838
167. R.S. Herbst, G. Giaccone, and J.H. Schiller Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2 J Clin Oncol 22 2004 785 794
168. K.J. Busam, P. Capodieci, R. Motzer, T. Kiehn, D. Phelan, and A.C. Halpern Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225 Br J Dermatol 144 2001 1169 1176
169. J.G. Paez, P.A. Janne, and J.C. Lee EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 2004 1497 1500
170. W. Pao, V. Miller, and M. Zakowski EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib Proc Natl Acad Sci USA 101 2004 13306 13311
171. T.J. Lynch, D.W. Bell, and R. Sordella Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2004 2129 2139
172. H. Shigematsu, L. Lin, and T. Takahashi Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers J Natl Cancer Inst 97 2005 339 346
173. J.W. Lee, Y.H. Soung, and S.Y. Kim Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck Clin Cancer Res 11 2005 2879 2882
174. Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal Growth Factor Receptor (EGFR) and HER2 gene amplification predict response to gefitinib therapy in advanced non-small cell lung cancer (NSCLC). Ann Oncol 2004;15 [Abstract 6820].
175. M.L. Amador, D. Oppenheimer, and S. Perea An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors Cancer Res 64 2004 9139 9143
176. H. Buerger, J. Packeisen, and A. Boecker Allelic length of a CA dinucleotide repeat in the egfr gene correlates with the frequency of amplifications of this sequence - first results of an inter-ethnic breast cancer study J Pathol 203 2004 545 550
177. G. Giaccone, R.S. Herbst, and C. Manegold Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 1 J Clin Oncol 22 2004 777 784
178. P. Matar, F. Rojo, M. Guzman, I. Rodriguez-Viltro, J. Arribas, and J. Baselga Combined anti-epidermal growth factor receptor (EGFR) treatment with a tyrosine kinase inhibitor gefitinib (ZD1839, "Iressa") and a monoclonal antibody (IMC-C225): evidence of synergy Proc Am Assoc Cancer Res 44 2003 800
179. S. Huang, E.A. Armstrong, S. Benavente, P. Chinnaiyan, and P.M. Harari Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor Cancer Res 64 2004 5355 5362
180. C.K. Goldman, J. Kim, W.L. Wong, V. King, T. Brock, and G.Y. Gillespie Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology Mol Biol Cell 4 1993 121 133
181. P. Traxler, P.R. Allegrini, and R. Brandt AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity Cancer Res 64 2004 4931 4941
182. L.F. Hennequin, E.S. Stokes, and A.P. Thomas Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors J Med Chem 45 2002 1300 1312
183. O.G. Yigitbasi, M.N. Younes, and D. Doan Tumor cell and endothelial cell therapy of oral cancer by dual tyrosine kinase receptor blockade Cancer Res 64 2004 7977 7984
184. S.R. Wedge, D.J. Ogilvie, and M. Dukes ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration Cancer Res 62 2002 4645 4655
185. F. Ciardiello, R. Caputo, and V. Damiano Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase Clin Cancer Res 9 2003 1546 1556
186. K.J. Williams, B.A. Telfer, and S. Brave ZD6474, a potent inhibitor of vascular endothelial growth factor signaling, combined with radiotherapy: schedule-dependent enhancement of antitumor activity Clin Cancer Res 10 2004 8587 8593
187. Heymach JV, Dong RP, Dimery I, et al. ZD6474, a novel antiangiogenic agent, in combination with docetaxel in patients with NSCLC: results of the run-in phase of a two-part, randomized phase II study. J Clin Oncol 2004;22 [Abstract 3051].
188. Hurwitz H, Holden SN, Eckhardt SG, et al. Clinical evaluation of ZD6474, an orally active inhibitor of VEGF signaling, in patients with solid tumors. Proc Am Soc Clin Oncol 2002;21 [Abstract 325].
189. Minami H, Ebi H, Tahara M, et al. A phase I study of an oral VEGF receptor tyrosine kinase inhibitor ZD6474, in Japanese patients with solid tumors. Proc Am Soc Clin Oncol 2003;22 [Abstract 778].
190. Y. He, Q. Zeng, and S.D. Drenning Inhibition of human squamous cell carcinoma growth in vivo by epidermal growth factor receptor antisense RNA transcribed from the U6 promoter J Natl Cancer Inst 90 1998 1080 1087
191. S. Endo, Q. Zeng, and N.A. Burke TGF-alpha antisense gene therapy inhibits head and neck squamous cell carcinoma growth in vivo Gene Ther 7 2000 1906 1914
192. J.R. Grandis, S.D. Drenning, and Q. Zeng Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo Proc Natl Acad Sci USA 97 2000 4227 4232
193. M. Schmidt, E. Vakalopoulou, D.W. Schneider, and W. Wels Construction and functional characterization of scFv(14E1)-ETA - a novel, highly potent antibody-toxin specific for the EGF receptor Br J Cancer 75 1997 1575 1584
194. W. Wels, R. Beerli, and P. Hellmann EGF receptor and p185erbB-2-specific single-chain antibody toxins differ in their cell-killing activity on tumor cells expressing both receptor proteins Int J Cancer 60 1995 137 144
195. M. Azemar, M. Schmidt, and F. Arlt Recombinant antibody toxins specific for ErbB2 and EGF receptor inhibit the in vitro growth of human head and neck cancer cells and cause rapid tumor regression in vivo Int J Cancer 86 2000 269 275
196. M. Schmidt, and W. Wels Targeted inhibition of tumour cell growth by a bispecific single-chain toxin containing an antibody domain and TGF alpha Br J Cancer 74 1996 853 862
197. J.H. Sampson, G. Akabani, and G.E. Archer Progress report of a phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors J Neurooncol 65 2003 27 35
198. G. Mishra, T.F. Liu, and A.E. Frankel Recombinant toxin DAB389EGF is cytotoxic to human pancreatic cancer cells Expert Opin Biol Ther 3 2003 1173 1180
199. Frankel AE, Liu TF, Thorburn AM, Tatter SB, Willingham MC. Recombinant toxin DAB389EGF produces regressions of human glioma xenografts in nude mice. J Clin Oncol 2004; 22 [Abstract 3101].
200. R. Perez-Soler, A. Chachoua, and L.A. Hammond Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer J Clin Oncol 22 2004 3238 3247
201. G.L. Rosner, W. Stadler, and M.J. Ratain Randomized discontinuation design: application to cytostatic antineoplastic agents J Clin Oncol 20 2002 4478 4484